Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 592

1.

Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.

Gong W, Dou H, Liu X, Sun L, Hou Y.

Clin Exp Pharmacol Physiol. 2012 Oct;39(10):886-93. doi: 10.1111/j.1440-1681.2012.12006.x.

PMID:
23013134
2.

Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.

Rahman MM, Bhattacharya A, Fernandes G.

J Lipid Res. 2006 Aug;47(8):1739-48. Epub 2006 May 15.

4.

Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.

Franco GC, Kajiya M, Nakanishi T, Ohta K, Rosalen PL, Groppo FC, Ernst CW, Boyesen JL, Bartlett JD, Stashenko P, Taubman MA, Kawai T.

Exp Cell Res. 2011 Jun 10;317(10):1454-64. doi: 10.1016/j.yexcr.2011.03.014. Epub 2011 Mar 21.

5.
6.

Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.

Kim MH, Ryu SY, Choi JS, Min YK, Kim SH.

J Cell Physiol. 2009 Dec;221(3):618-28. doi: 10.1002/jcp.21892.

PMID:
19653230
7.

Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.

Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M.

Life Sci. 2007 Mar 13;80(14):1311-8. Epub 2007 Jan 23.

PMID:
17306833
8.

Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.

Shim KS, Ma CJ, Kim DS, Ma JY.

J Med Food. 2011 Nov;14(11):1439-47. doi: 10.1089/jmf.2010.1502. Epub 2011 Sep 1.

PMID:
21883017
9.

Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells.

Yoon WJ, Kim KN, Heo SJ, Han SC, Kim J, Ko YJ, Kang HK, Yoo ES.

Biochem Biophys Res Commun. 2013 May 17;434(4):892-7. doi: 10.1016/j.bbrc.2013.04.046. Epub 2013 Apr 20.

PMID:
23611776
10.

The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.

Kim HS, Suh KS, Sul D, Kim BJ, Lee SK, Jung WW.

Int J Mol Med. 2012 Feb;29(2):169-77. doi: 10.3892/ijmm.2011.822. Epub 2011 Oct 31.

PMID:
22038020
11.

Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.

Kang MR, Jo SA, Yoon YD, Park KH, Oh SJ, Yun J, Lee CW, Nam KH, Kim Y, Han SB, Yu J, Rho J, Kang JS.

Mar Drugs. 2014 Nov 24;12(11):5643-56. doi: 10.3390/md12115643.

12.

Molecular mechanism of thiazolidinedione-mediated inhibitory effects on osteoclastogenesis.

Zhao D, Shi Z, Warriner AH, Qiao P, Hong H, Wang Y, Feng X.

PLoS One. 2014 Jul 17;9(7):e102706. doi: 10.1371/journal.pone.0102706. eCollection 2014.

13.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

14.

Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.

Ang ES, Pavlos NJ, Chai LY, Qi M, Cheng TS, Steer JH, Joyce DA, Zheng MH, Xu J.

J Cell Physiol. 2009 Dec;221(3):642-9. doi: 10.1002/jcp.21898.

PMID:
19681045
15.

Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages.

Kim JL, Kang MK, Gong JH, Park SH, Han SY, Kang YH.

Mol Nutr Food Res. 2012 Aug;56(8):1223-33. doi: 10.1002/mnfr.201100831. Epub 2012 Jun 15.

PMID:
22700286
16.

Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone.

Ghayor C, Correro RM, Lange K, Karfeld-Sulzer LS, Grätz KW, Weber FE.

J Biol Chem. 2011 Jul 8;286(27):24458-66. doi: 10.1074/jbc.M111.223297. Epub 2011 May 25.

17.

Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.

Nepal M, Choi HJ, Choi BY, Yang MS, Chae JI, Li L, Soh Y.

Eur J Pharmacol. 2013 Sep 5;715(1-3):96-104. doi: 10.1016/j.ejphar.2013.06.002. Epub 2013 Jun 19.

PMID:
23791609
18.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

19.

Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.

Cheng CP, Sheu MJ, Sytwu HK, Chang DM.

Rheumatology (Oxford). 2013 Apr;52(4):609-22. doi: 10.1093/rheumatology/kes343. Epub 2012 Dec 7.

PMID:
23221330
20.

Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways.

Wei ZF, Tong B, Xia YF, Lu Q, Chou GX, Wang ZT, Dai Y.

PLoS One. 2013;8(3):e59171. doi: 10.1371/journal.pone.0059171. Epub 2013 Mar 11.

Supplemental Content

Support Center